Literature DB >> 10714235

GnRH receptor and apoptotic signaling.

A Imai1, T Tamaya.   

Abstract

In addition to its hypophysiotropic action, gonadotropin-releasing hormone (GnRH) can modify activity in extrapituitary organs and peripheral tumors. GnRH analogs are the preferred treatment for advanced and even metastatic or recurring carcinomas in vivo and in vitro. Hormone-responsive tumors undergo apoptosis with the appropriate stimulus; GnRH-induced tumor growth arrest may result from stimulated apoptotic cell death. The sensitivity of tumors and normal tissue to GnRH is strongly associated with the possession of receptors for GnRH as well as other hormonal control. Despite the lack of a precise apoptotic signaling cascade through GnRH receptors, biochemical events observed within a plasma membrane appear to constitute the most convincing evidence that the membrane event is primarily stimulated during cell activation by GnRH. GnRH receptors in tumors differ from those in pituitary gonadotrophs in some aspects, in particular with regard to the transmembrane signaling cascade. The intramembranous phenomena that occur independently of the contribution of other organelles upon tumoral GnRH receptor engagement include (i) activation of phosphotyrosine phosphatase and loss of phosphotyrosine from the endogenous membrane protein and (ii) phosphoinositide and perhaps sphingomyelin cleavage producing lipid-originated second messengers. GnRH has also been demonstrated to increase Fas ligand expression within plasma membrane, which is known to promote apoptotic cell death through attack on Fas-positive cells within tumors. The Fas-Fas ligand complex might, at least in part, account for the antiproliferative action of the hormone. An understanding of the relationship between the extracellular (hormonal) stimuli that leads to cell death and the intracellular events regulating growth arrest on GnRH action may fundamentally help clarify the therapeutic approach to all hormone-dependent carcinomas that respond to stimuli that lead to apoptosis. In this chapter, we review the recent literature and the results of our studies on GnRH-induced membrane events and summarize what is currently known about this promising antiproliferative function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714235     DOI: 10.1016/s0083-6729(00)59002-5

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  7 in total

Review 1.  Preservation of female fertility during cancer treatment.

Authors:  Atsushi Imai; Tatsuro Furui; Akio Yamamoto
Journal:  Reprod Med Biol       Date:  2008-02-01

2.  Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells.

Authors:  Shou-Liang Gong; Gang Zhao; Hong-Guang Zhao; Wen-Tian Lu; Guang-Wei Liu; Ping Zhu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.374

3.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.

Authors:  G Pérez-Tenorio; O Stål
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

4.  Gonadotropin‑releasing hormone inhibits the proliferation and motility of nasopharyngeal carcinoma cells.

Authors:  Loong Hung Teng; Munirah Ahmad; Wayne Tiong Weng Ng; Subathra Sabaratnam; Maria Ithaya Rasan; Ishwar Parhar; Alan Soo Beng Khoo
Journal:  Mol Med Rep       Date:  2015-07-03       Impact factor: 2.952

Review 5.  Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions.

Authors:  Fabrizio Fontana; Monica Marzagalli; Marina Montagnani Marelli; Michela Raimondi; Roberta M Moretti; Patrizia Limonta
Journal:  Int J Mol Sci       Date:  2020-12-14       Impact factor: 5.923

Review 6.  Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer.

Authors:  Fabrizio Fontana; Patrizia Limonta
Journal:  Cells       Date:  2021-05-07       Impact factor: 6.600

7.  Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment.

Authors:  Meng Li; Hanmei Xu; Junzhi Wang
Journal:  Acta Pharm Sin B       Date:  2019-11-02       Impact factor: 11.413

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.